Annual EBITDA
-$16.80 M
+$6.28 M+27.21%
31 December 2023
Summary:
Akari Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$16.80 million, with the most recent change of +$6.28 million (+27.21%) on 31 December 2023. During the last 3 years, it has risen by +$1.17 million (+6.51%). AKTX annual EBITDA is now -2021.46% below its all-time high of -$792.00 thousand, reached on 31 December 2010.AKTX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$2.83 M
+$4.68 M+62.36%
01 September 2024
Summary:
Akari Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$2.83 million, with the most recent change of +$4.68 million (+62.36%) on 01 September 2024. Over the past year, it has increased by +$44.00 thousand (+1.53%). AKTX quarterly EBITDA is now -143.66% below its all-time high of $6.47 million, reached on 31 December 2015.AKTX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$27.24 M
+$44.00 K+0.16%
01 September 2024
Summary:
Akari Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$27.24 million, with the most recent change of +$44.00 thousand (+0.16%) on 01 September 2024. Over the past year, it has dropped by -$15.78 million (-137.69%). AKTX TTM EBITDA is now -1346.84% below its all-time high of -$1.88 million, reached on 31 March 2014.AKTX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AKTX EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +27.2% | +1.5% | -137.7% |
| 3 y3 years | +6.5% | -93.2% | -49.4% |
| 5 y5 years | +28.4% | +9.2% | -86.2% |
AKTX EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +27.2% | -93.2% | +74.2% | -217.1% | +0.2% |
| 5 y | 5 years | at high | +28.4% | -1049.3% | +74.2% | -217.1% | +0.2% |
| alltime | all time | -2021.5% | +60.2% | -143.7% | +93.8% | -1346.8% | +46.1% |
Akari Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$2.83 M(-62.4%) | -$27.24 M(-0.2%) |
| June 2024 | - | -$7.51 M(+25.6%) | -$27.29 M(+14.8%) |
| Mar 2024 | - | -$5.98 M(-45.3%) | -$23.78 M(+6.2%) |
| Dec 2023 | -$16.80 M(-27.2%) | -$10.94 M(+281.0%) | -$22.40 M(+95.4%) |
| Sept 2023 | - | -$2.87 M(-28.2%) | -$11.46 M(+33.4%) |
| June 2023 | - | -$4.00 M(-12.9%) | -$8.59 M(-17.4%) |
| Mar 2023 | - | -$4.59 M(-21.0%) | -$10.41 M(-43.4%) |
| Dec 2022 | -$23.08 M(+34.1%) | - | - |
| June 2022 | - | -$5.82 M(+10.9%) | -$18.39 M(+8.8%) |
| Mar 2022 | - | -$5.24 M(-10.7%) | -$16.91 M(-1.8%) |
| Dec 2021 | -$17.21 M(-4.2%) | -$5.87 M(+301.5%) | -$17.21 M(-5.6%) |
| Sept 2021 | - | -$1.46 M(-66.2%) | -$18.23 M(+7.1%) |
| June 2021 | - | -$4.33 M(-22.0%) | -$17.02 M(-8.5%) |
| Mar 2021 | - | -$5.55 M(-19.5%) | -$18.60 M(+3.5%) |
| Dec 2020 | -$17.97 M(+6.1%) | -$6.89 M(+2703.8%) | -$17.97 M(-4.9%) |
| Sept 2020 | - | -$245.90 K(-95.8%) | -$18.90 M(-13.2%) |
| June 2020 | - | -$5.91 M(+20.0%) | -$21.77 M(-0.5%) |
| Mar 2020 | - | -$4.92 M(-37.1%) | -$21.88 M(+29.2%) |
| Dec 2019 | -$16.94 M(-27.7%) | -$7.82 M(+151.3%) | -$16.94 M(+15.8%) |
| Sept 2019 | - | -$3.11 M(-48.4%) | -$14.63 M(-14.9%) |
| June 2019 | - | -$6.03 M(<-9900.0%) | -$17.19 M(-10.2%) |
| Mar 2019 | - | $17.50 K(-100.3%) | -$19.14 M(-18.4%) |
| Dec 2018 | -$23.45 M | -$5.51 M(-3.0%) | -$23.45 M(-18.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2018 | - | -$5.68 M(-28.8%) | -$28.84 M(-9.0%) |
| June 2018 | - | -$7.97 M(+85.5%) | -$31.70 M(+2.0%) |
| Mar 2018 | - | -$4.30 M(-60.6%) | -$31.07 M(-11.3%) |
| Dec 2017 | -$35.04 M(+28.8%) | -$10.90 M(+27.8%) | -$35.04 M(+3.1%) |
| Sept 2017 | - | -$8.53 M(+16.3%) | -$33.98 M(+8.0%) |
| June 2017 | - | -$7.34 M(-11.3%) | -$31.46 M(-0.5%) |
| Mar 2017 | - | -$8.27 M(-15.9%) | -$31.64 M(+16.3%) |
| Dec 2016 | -$27.21 M(-35.6%) | -$9.84 M(+63.7%) | -$27.21 M(+149.8%) |
| Sept 2016 | - | -$6.01 M(-19.9%) | -$10.89 M(-78.5%) |
| June 2016 | - | -$7.51 M(+95.4%) | -$50.56 M(+13.9%) |
| Mar 2016 | - | -$3.84 M(-159.4%) | -$44.39 M(+5.1%) |
| Dec 2015 | -$42.25 M(+2081.2%) | $6.47 M(-114.2%) | -$42.24 M(-15.2%) |
| Sept 2015 | - | -$45.68 M(+3315.7%) | -$49.82 M(+1042.7%) |
| June 2015 | - | -$1.34 M(-20.9%) | -$4.36 M(-18.5%) |
| Mar 2015 | - | -$1.69 M(+52.1%) | -$5.35 M(-3.5%) |
| Dec 2014 | -$1.94 M(-43.3%) | -$1.11 M(+408.4%) | -$5.54 M(+25.1%) |
| Sept 2014 | - | -$218.80 K(-90.6%) | -$4.43 M(+5.2%) |
| June 2014 | - | -$2.33 M(+23.7%) | -$4.21 M(+123.7%) |
| Mar 2014 | - | -$1.88 M | -$1.88 M |
| Dec 2013 | -$3.42 M(+1.4%) | - | - |
| Dec 2012 | -$3.37 M(+49.9%) | - | - |
| Dec 2011 | -$2.25 M(+183.7%) | - | - |
| Dec 2010 | -$792.00 K | - | - |
FAQ
- What is Akari Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Akari Therapeutics?
- What is Akari Therapeutics annual EBITDA year-on-year change?
- What is Akari Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Akari Therapeutics?
- What is Akari Therapeutics quarterly EBITDA year-on-year change?
- What is Akari Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Akari Therapeutics?
- What is Akari Therapeutics TTM EBITDA year-on-year change?
What is Akari Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of AKTX is -$16.80 M
What is the all time high annual EBITDA for Akari Therapeutics?
Akari Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$792.00 K
What is Akari Therapeutics annual EBITDA year-on-year change?
Over the past year, AKTX annual earnings before interest, taxes, depreciation & amortization has changed by +$6.28 M (+27.21%)
What is Akari Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of AKTX is -$2.83 M
What is the all time high quarterly EBITDA for Akari Therapeutics?
Akari Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $6.47 M
What is Akari Therapeutics quarterly EBITDA year-on-year change?
Over the past year, AKTX quarterly earnings before interest, taxes, depreciation & amortization has changed by +$44.00 K (+1.53%)
What is Akari Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of AKTX is -$27.24 M
What is the all time high TTM EBITDA for Akari Therapeutics?
Akari Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is -$1.88 M
What is Akari Therapeutics TTM EBITDA year-on-year change?
Over the past year, AKTX TTM earnings before interest, taxes, depreciation & amortization has changed by -$15.78 M (-137.69%)